CJC-1295 NO DAC

Description

Introduction to CJC-1295 (Without DAC) – Research Use Only

CJC-1295 without DAC is a synthetic peptide analog of Growth Hormone-Releasing Hormone (GHRH). Its structure is designed to stimulate the pituitary gland to release endogenous growth hormone (GH) in a pulsatile manner, aligning with the body’s natural GH rhythm. Unlike versions of CJC-1295 with Drug Affinity Complex (DAC), the non-DAC form has a shorter half-life, making it suitable for research on acute GH pulse enhancement rather than continuous stimulation.

Key Areas of Research

1. Growth Hormone Modulation

CJC-1295 has been shown in research models to increase GH and IGF-1 levels. These hormones are essential for tissue growth, metabolism, and cellular repair. Studies have explored the peptide’s use in contexts such as:

• Muscle hypertrophy models (muscle fiber growth and regeneration)
• Body composition modulation
• Recovery following exercise or soft tissue injury

2. Muscle Growth and Recovery

Preclinical research suggests that periodic stimulation of GH via CJC-1295 without DAC may enhance protein synthesis and myogenic activity. This has led to its inclusion in studies of muscle regeneration, particularly in recovery from exertion or injury.

3. Lipolysis and Fat Metabolism

CJC-1295 has been studied in the context of GH-mediated lipolysis, or fat breakdown. Growth hormone increases the availability of free fatty acids for energy, making CJC-1295 a peptide of interest in adipose tissue metabolism models.

4. Sleep Quality and Hormonal Pulsatility

Because endogenous GH is primarily secreted during slow-wave sleep, CJC-1295’s pulsatile action may support sleep architecture and restorative processes. Research includes:

• Circadian rhythm and hormonal entrainment
• Deep sleep enhancement models

5. Skin Health and Collagen

GH and IGF-1 play a role in collagen synthesis and dermal regeneration. Research suggests that CJC-1295 may support skin elasticity and structure via indirect GH pathways, contributing to ongoing investigations into aging and dermatological integrity.

6. Immune Function

CJC-1295 has also been studied for its potential role in immunomodulation through GH and IGF-1. These hormones are known to influence thymic function and immune cell turnover in various models.

Mechanism of Action

CJC-1295 without DAC works by mimicking growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on the anterior pituitary, stimulating pulsatile GH release. This design allows for more physiological GH rhythms, as opposed to continuous stimulation seen with long-acting DAC-modified peptides.

Supporting References (Scientific and Medical Journals)

• Teichman, S. L. et al. (2006). Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(11), 4792–4797. https://doi.org/10.1210/jc.2006-0019
• Walker, R. F. et al. (2001). Growth hormone-releasing peptides stimulate GH secretion and modulate lipolysis in aged rats. Neurobiology of Aging, 22(5), 857–863. https://doi.org/10.1016/S0197-4580(01)00223-0
• Ghigo, E. et al. (1994). Effects of GH-releasing peptides on GH and cortisol secretion in humans. Neuroendocrinology, 59(2), 133–138. https://doi.org/10.1159/000126678
• Grinspoon, S. et al. (2007). Effects of GH secretagogues on fat and muscle mass in men with HIV-associated lipodystrophy. Clinical Infectious Diseases, 45(S4), S385–S393. https://doi.org/10.1086/522986
• van den Berghe, G. (2001). Anabolic effects of growth hormone in catabolic conditions. Hormone Research, 56(Suppl. 1), 38–43. https://doi.org/10.1159/000048142

Disclaimer:
CJC-1295 (without DAC) is a research chemical and is not approved by the FDA for human consumption or therapeutic use. It is intended strictly for laboratory research purposes only. Any discussion of effects is based on animal studies and in vitro research models, and does not imply human efficacy or safety. This product is not intended to diagnose, treat, cure, or prevent any disease.